Top Markets
Coin of the day
NanoVibronix, Inc. NanoVibronix, Inc.

NanoVibronix, Inc.

NAOV
Rangering i aksjer #37687
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd.,... NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.
Aksjekurs
$1.90
Sist synkronisert: 2026-03-11
Markedsverdi
$1.51M
Endring (1 dag)
-41.54%
Endring (1 år)
-67.58%
Land
US
Handel NanoVibronix, Inc. (NAOV)

Kategori

Inntekter for NanoVibronix, Inc. (NAOV)
Inntekter i 2026 TTM: 0
Ifølge NanoVibronix, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for NanoVibronix, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US